Functional Groups in Drug Action: Hydrocarbons and Halides

Targeted Therapy: Daraxonrasib

  • Daraxonrasib (Rasonque®, RMC-6236): An oral, non-covalent pan-RAS(ON) inhibitor developed by Revolution Medicines (Redwood City, CA).
  • Regulatory Milestone: Approved by the FDA on August 26, 2026, as a first-in-class targeted therapy for metastatic pancreatic cancer.
  • Historical Context: Prior to key structural insights published in 2013 on K-Ras(G12C) allosteric control (Ostrem et al.), RAS proteins were widely considered undruggable.

Chemical structure of daraxonrasib (RMC-6236)

Hydrocarbon Architecture and Hybridization

  • Alkanes (sp3sp^3 Hybridization):
    • Formed by mixing one ss and three pp atomic orbitals to yield four identical sp3sp^3 orbitals (25%25\% S, 75%75\% P character).
    • Adopt a tetrahedral geometry with characteristic bond angles of 109.5∘109.5^\circ.
    • Ethane contains a C-C σ\sigma bond length of 153 pm153\,\text{pm} and H-C-C angles of ∼111∘\sim 111^\circ.
    • Boiling points scale directly with carbon chain length due to increased London dispersion interactions.

Formation of four tetrahedral sp3 orbitals from s and p orbitals

  • Alkenes (sp2sp^2 Hybridization):
    • Hybridization of one ss and two pp orbitals creates three planar sp2sp^2 orbitals (33%33\% S, 66%66\% P character), leaving one unhybridized pp orbital at 90∘90^\circ.
    • Consists of one σ\sigma bond and one π\pi bond, creating a rigid planar center.
    • Geometrical Isomerism: cis-Oleic acid (m.p. 13 ∘C13\,^\circ\text{C}) exhibits a lower melting point than trans-Oleic acid (m.p. 43 ∘C43\,^\circ\text{C}) due to poorer packing efficiency and diminished van der Waals contact.

Orbital overlap forming a carbon-carbon double bond with sigma and pi bonds

  • Cycloalkanes:
    • Isomeric with alkenes (CnH2nC_n H_{2n}); slightly less hydrophobic and more rigid than open-chain counterparts.
    • Serve as defined scaffolds to hold functional groups in precise spatial arrangements (e.g., cyclohexane chair conformation, cis/trans-Decalin, androstane).

Chemical Forces and Pharmacological Relevance

  • Intermolecular vs. Intramolecular Forces:
    • Intermolecular (between molecules): Dispersion (0–2 kJ mol−10\text{--}2\,\text{kJ\,mol}^{-1}), Dipole-dipole (2–10 kJ mol−12\text{--}10\,\text{kJ\,mol}^{-1}), Hydrogen bonding (10–20 kJ mol−110\text{--}20\,\text{kJ\,mol}^{-1}), Ion-dipole (10–40 kJ mol−110\text{--}40\,\text{kJ\,mol}^{-1}).
    • Intramolecular (within molecules): Covalent bonds (100–400 kJ mol−1100\text{--}400\,\text{kJ\,mol}^{-1}), Ion-ion (100–1000 kJ mol−1100\text{--}1000\,\text{kJ\,mol}^{-1}).
    • Zero attractive force is achievable only in ideal gases.

Spectrum of intermolecular and intramolecular forces with interaction energies

  • Structure-Activity Relationship (SAR) of Alkyl Chains:
    • Modifying linear alkyl chains on opioids significantly shifts agonist versus antagonist activity:
    • −CH3-\text{CH}_3 (Morphine): Strong agonist.
    • −CH2CH3-\text{CH}_2\text{CH}_3: Moderate agonist, weak antagonist.
    • −CH2CH2CH3-\text{CH}_2\text{CH}_2\text{CH}_3: Weak agonist, moderate antagonist.
    • −CH2CH2CH2CH3-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3: Inactive.
    • −CH2CH2–phenyl-\text{CH}_2\text{CH}_2\text{--}\text{phenyl}: Agonist potency 14×14\times that of morphine.

Aromatic Hydrocarbons and Metabolism

  • Aromaticity Criteria:
    • Cyclic, planar, fully conjugated π\pi-system conforming to Hückel's Rule (4n+24n+2 π\pi-electrons).
    • Enables key binding interactions with receptors via π–π\pi\text{--}\pi stacking and cation-π\pi interactions (e.g., Acetylcholine in nicotinic ACh receptors, Etomidate with Phe in GABAA\text{GABA}_A receptors).
  • Polycyclic Aromatic Hydrocarbons (PAHs):
    • Fused ring systems without heteroatoms produced via incomplete combustion of fuel or organic matter (e.g., Benzo[a]pyrene / BaP).
    • Bioactivated by CYP1A1/CYP1B1 and epoxide hydrolase into reactive diol epoxides (BPDE) that form carcinogenic DNA adducts at N6N^6 of adenine and N2N^2 of guanine.

!Metabolic activation of Benzo[a]pyrene to BPDE and formation of DNA adducts

  • Hydrocarbon Metabolic Pathways:
    • Aliphatic Oxidation: CYP450 enzymes hydroxylate alkanes at allylic, benzylic, or heteroatom-adjacent sites (e.g., Pentobarbital to 3-Hydroxy-pentobarbital).
    • Deuteration Strategy: Replacing metabolically vulnerable C-H bonds with C-D bonds reduces oxidation rates up to 7-fold when C-H cleavage is rate-limiting (DKIE=kHkD\text{DKIE} = \frac{k_H}{k_D}), prolonging drug half-life (e.g., Deutetrabenazine / Austedo®).
    • Arene Hydroxylation: CYP450 oxidizes electron-rich aromatic rings. Electron-withdrawing groups and 6-membered heteroarenes decrease oxidation susceptibility, whereas 5-membered heteroarenes increase it (e.g., Phenylbutazone to Oxyphenbutazone; Phenytoin).

Halogenated Hydrocarbons in Medicinal Chemistry

  • Physicochemical Effects:
    • Halogens enhance lipophilicity, induce conformational bias, pull electron density inductively, and engage in halogen bonding.
    • Fluorine is slightly larger than hydrogen; Chlorine is similar in steric size to a methyl group.

Electrostatic potential maps of halo-substituted benzene derivatives showing electron density variations

  • Medicinal Applications of Halogenated Groups:
    • Inert Modifiers: Paroxetine (Paxil®) and Chloramphenicol (Chloromycetin®) contain stable halogen substituents.
    • Reactive Warheads: Melphalan (Alkeran®) utilizes a bis(chloroethyl)amine nitrogen mustard motif for DNA alkylation.
    • Fluorine Properties: Highly electronegative, polarizes C-F bonds strongly, blocks metabolic soft spots, serves as a weak H-bond acceptor, and provides an avenue for 18F^{18}\text{F} PET radiolabeling (e.g., Lansoprazole, Celecoxib, Ciprofloxacin, Atorvastatin).
    • Inhalational Anesthetics: Small hydrophobic halogenated compounds (Halothane, Sevoflurane, Desflurane, Isoflurane) modulate GABAA\text{GABA}_A receptors; halogenated ethers replaced Halothane to prevent liver injury.